Skip to main content

Table 2 The individual effect of each metabolite on UL by using weighted logistic regression

From: Urinary phytoestrogens and the risk of uterine leiomyomata in US women

Metabolites of urinary phytoestrogen

Model 1

Model 2

OR (95% CI)

P

OR (95% CI)

P

Daidzein

 Tertile 1

Ref

 

Ref

 

 Tertile 2

0.93 (0.52–1.68)

0.816

0.91 (0.46–1.80)

0.787

 Tertile 3

1.13 (0.69–1.85)

0.625

1.26 (0.57–2.77)

0.565

Genistein

 Tertile 1

Ref

 

Ref

 

 Tertile 2

1.24 (0.77–1.98)

0.369

1.21 (0.68–2.15)

0.507

 Tertile 3

1.15 (0.69–1.91)

0.594

1.00 (0.50–1.98)

0.989

Equol

 Tertile 1

Ref

 

Ref

 

 Tertile 2

1.17 (0.71–1.94)

0.533

1.19 (0.70–2.02)

0.506

 Tertile 3

1.92 (1.07–3.43)

0.029

1.92 (1.09–3.38)

0.024

O-desmethylangolensin

 Tertile 1

Ref

 

Ref

 

 Tertile 2

1.21 (0.67–2.18)

0.528

1.11 (0.61–2.00)

0.729

 Tertile 3

1.03 (0.63–1.69)

0.891

0.81 (0.47–1.40)

0.449

Enterodiol

 Tertile 1

Ref

 

Ref

 

 Tertile 2

0.78 (0.43–1.41)

0.407

0.75 (0.41–1.37)

0.347

 Tertile 3

1.18 (0.74–1.90)

0.476

1.07 (0.66–1.73)

0.772

Enterolactone

 Tertile 1

Ref

 

Ref

 

 Tertile 2

0.65 (0.37–1.15)

0.139

0.61 (0.34–1.11)

0.107

 Tertile 3

1.16 (0.68–2.00)

0.578

1.06 (0.59–1.89)

0.852

  1. UL uterine leiomyomata, Ref reference, OR odds ratio, CI confidence interval
  2. Model 1: adjusted age, race/ethnicity, marital status, drinking status, body mass index, waist circumference, menopausal status, ovary removed status, use of female hormones, hormones/hormone modifiers and total energy
  3. Model 2: further adjusted for other metabolites of urinary phytoestrogen on the basis of Model 2